Clinical ink Forms Strategic Alliance with Boston Clinical Research Institute
Alliance Amplifies Clinical ink's Scientific Expertise to Support Improved Patient Outcomes
Horsham, PA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Today Clinical ink, a global life science technology company, announces an strategic alliance with The Boston Clinical Research Institute (BCRI), an Academic Research Organization (ARO) based in Boston, Massachusetts. The alliance will combine BCRI’s leadership in clinical strategy, therapeutic area expertise, and academic collaboration with Clinical ink’s expertise in eSource technology, including Direct Data Capture (DDC), electronic Clinical Outcomes Assessments (eCOA), and digital biomarkers.
BCRI provides scientific consultancy in study design, patient-centric modalities, endpoint selection, and complex data analysis by leveraging expert clinicians and key opinion leaders from premier medical institutions—with a goal to help advance health and quality of life around the world. To date, the institute has managed 450 studies which have enrolled over 160,000 patients, and has played a role in more than 50 FDA submissions.
"We are extremely pleased to announce this alliance," said Michael Gibson, MD, President and Chief Executive Officer of BCRI. “The path forward for global clinical trials will be forged via the expert design and planning of therapeutic thought leaders who will recommend the implementation of innovative and clinically-relevant eSource technology.”
Commenting on the alliance, Dr. Jonathan Goldman, MD, the Chief Executive Officer of Clinical ink, said, "We are delighted that Dr. Gibson and BCRI have aligned with Clinical ink. This relationship provides our trusted Sponsor and CRO partners access to a breadth of clinical and key opinion leader expertise in trial design, as well as clinical and digital endpoint selection across a full range of therapeutic areas.”
About Clinical Ink
Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials.
About Boston Clinical Research Institute
The Boston Clinical Research Institute is a non-profit academic research organization (ARO), based in Boston, but with experience in research that spans the world. Our team delivers insights, innovation, and leadership to develop creative solutions that reduce obstacles to implementation and enrollment of clinical trials. We collaborate with the world’s leading researchers from national and international institutions to design, implement, and complete clinical trials, and then develop programs to translate the results into clinical practice. Our entire team is fiercely committed to finding creative solutions and delivering timely research that helps advance health and quality of life around the world.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Innovative Producer, Filmmaker and Author Mick Ebeling to Join Duck Creek’s Formation ’23 as Keynote Speaker27.3.2023 14:30:00 CEST | Press release
Ebeling will discuss pushing the bar and making the inconceivable, the unbelievable and the impossible, not impossible Boston, March 27, 2023 (GLOBE NEWSWIRE) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, welcomes Mick Ebeling as its Formation ’23 keynote speaker. Formation, Duck Creek’s annual user conference, attracts the world’s leading insurance industry and technology minds and takes place in Orlando, FL, May 8-10, 2023. Ebeling is the founder and CEO of Not Impossible, a critically acclaimed, award-winning social lab and production company that taps into the power of technology and story to change the world. Formation '23 will empower the P&C and general insurance community with the insights, technology, and inspiration to build better human experiences. As the industry comes together to collaborate and reimage the future of P&C technology, the conference’s theme, “building together,” is me
NGS Group AB: Kallelse till årsstämma i NGS Group AB (publ)27.3.2023 14:15:00 CEST | Pressemelding
Aktieägarna i NGS Group AB (publ), org. nr 556535-1128 ("Bolaget") kallas härmed till årsstämma torsdagen den 27 april 2023, kl. 15.00 i Bolagets lokaler på Kungsgatan 12 i Stockholm. Inregistrering till stämman påbörjas klockan 14:30. Rätt att delta på bolagsstämman Aktieägare som vill delta på bolagsstämman ska: dels vara införd i den av Euroclear Sweden AB förda aktieboken avseende förhållandena per avstämningsdagen onsdagen den 19 april 2023,dels anmäla sig för deltagande på bolagsstämman till Bolaget under adress NGS Group AB (publ), Thomas Plate, Kungsgatan 12, 111 35 Stockholm, per telefon 0768-949 239 eller via e-post till firstname.lastname@example.org. Anmälan ska vara Bolaget tillhanda senast fredagen den 21 april 2023. Vid anmälan ska uppges namn, person- eller organisationsnummer (eller motsvarande), e‑postadress eller telefonnummer dagtid, samt antal aktier och eventuella biträden. Förvaltarregistrerade aktier För att ha rätt att delta i stämman måste en aktieägare som låtit förvaltarr
Transactions in connection with share buyback programme27.3.2023 14:07:42 CEST | Press release
On 8 February 2023, Pandora announced a new share buyback programme, cf. Company announcement no. 769. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation). The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes. Under the programme Pandora will repurchase shares for an aggregate maximum amount of DKK 2.4 billion with an intention to go up to a total of DKK 5.0 billion during the next 12 months, depending on how the macroeconomic climate develops throughout the year. The programme commenced on 8 February 2023, cf. Company Announcement no. 769, and will conclude no later than 2 February 2024. The following transactions have been made under the programme: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated under the programme1,180,000760,396,825 20 Ma
Zoom announces the expansion of Zoom IQ, the smart companion that empowers collaboration and unlocks potential27.3.2023 14:01:10 CEST | Press release
Zoom uses OpenAI technologies to bolster a unique federated approach to AI based on flexibility SAN JOSE, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Today at Enterprise Connect, Zoom Video Communications, Inc. (NASDAQ: ZM) announced the expansion of Zoom IQ, a smart companion that empowers collaboration and unlocks people’s potential by summarizing chat threads, organizing ideas, drafting content for chats, emails, and whiteboard sessions, creating meeting agendas, and more. The company also announced it will use OpenAI to bolster its unique federated approach to AI based on flexibility. Zoom’s federated approach to AI leverages its own proprietary AI models, those from leading AI companies– such as OpenAI –and select customers’ own models. With this flexibility to incorporate multiple types of models, Zoom’s goal is to provide the most value for its customers' diverse needs. These models can also be customized to perform better for a customer, based on their vocabulary and requirement
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences27.3.2023 14:00:00 CEST | Press release
BOSTON and LONDON, March 27, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Genomic Medicines and Rare Disease Days Date: Monday, April 3, 2023 Location: New York, NY Fireside Chat: 9:35 AM ET Event: Jefferies & Venrock Boston Biotech Summit Date: Wednesday, April 12, 2023 Where applicable, the presentation slides and/or a link to the live webcast of the event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medi